<DOC>
	<DOC>NCT01083732</DOC>
	<brief_summary>To investigate the safety and tolerability of dabigatran etexilate solution in children and to obtain preliminary pharmacokinetic/pharmacodynamic data</brief_summary>
	<brief_title>Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to &lt; 12 Years of Age</brief_title>
	<detailed_description>Purpose:</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criteria: 1. males or females 1 to less than 12 years of age 2. objective diagnosis of primary VTE 3. completion of planned treatment course with LMWH or OAC for primary VTE 4. written informed consent by parent (legal guardian) and patient assent (if applicable) Exclusion criteria: 1. weight less than 9 kg 2. conditions associated with increased risk of bleeding 3. patients who have any condition that would not allow safe participation in study Note: Further exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>